A Study to Validate DNA Methylation Markers for Universal and Site-specific Guided Cancer Detection

Overview

About this study

The purpose of this study is to validate candidate universal and site-specific methylated DNA markers (MDMs) in DNA extracted from formalin-fixed paraffin embedded primary tumor and control specimens.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria - Aim 1 Tissue:

  • Adults, age >18 years old.

Cases

  • Patient has a biopsy confirmed diagnosis of target histology.
  • Tissue samples from synchronous or metachronous primary cancers may be used as long as they are clearly of a different target organ.
  • Tumors from patients with an underlying genetic disorder pre-disposing to cancer may be included as long as they are stratified from those without.

Controls

  • Patient does not have the diagnosis of target histology.

Exclusion Criteria - Aim 1 Tissue:

  • Individuals under 18 years of age.

Cases and Controls:

  • Patient has had any transplants prior to tissue collection.
  • Patient has received chemotherapy class drugs within 5 years prior to tissue collection.

Cases:

  • Patient has had radiation to the current target lesion prior to tissue collection.
  • Patient has multi-centric/multi-focal breast cancer with differing genetic profiles (ER/HER2/PR status differ; if multiple masses are present and not all are tested then exclude patient).
  • Patient has bilateral breast cancer/DCIS.

Inclusion Criteria - Aim 2 Blood:

Cases

  • Patient has a biopsy confirmed diagnosis of target histology or radiographic criteria that are unequivocal for diagnosis (example, meets radiographic criteria for hepatocellular carcinoma)

Controls

  • Patient does not have a diagnosis of the target histology.

Exclusion Criteria - Aim 2 Blood:

Cases and Controls

  • Patient has known cancer outside of the target cancer 5 years prior to blood collection (not including basal cell or squamous cell skin cancers).
  • Patient has had any transplants prior to blood collection.
  • Patient has had any prior radiation therapy to the target lesion prior to blood collection.
  • Patient has had a biopsy to the target organ and/or lesion within 3 days before blood collection.

Cases

  • Patient has had an intervention to completely remove current target pathology.
  • The current target pathology is a recurrence.
  • Patient has multi-centric/multi-focal breast cancer with differing genetic profiles (ER/HER2/PR status differ; if multiple masses are present and not all are tested then exclude patient).
  • Patient has bilateral breast cancer/DCIS.

Inclusion CriteriaAim 3 Urine

Cases:

  • Patient has a biopsy confirmed diagnosis of target histology or radiographic criteria that are unequivocal for diagnosis (example, meets radiographic criteria for hepatocellular carcinoma).

Controls:

  • Patient does not have a diagnosis of the target histology.

Exclusion Criteria: Aim 3 Urine

  • Patient has known cancer outside of the target cancer 5 years prior to urine collection (not including basal cell or squamous cell skin cancers).
  • Patient has received chemotherapy class drugs in the 5 years prior to urine collection.
  • Patient has had any prior radiation therapy to the target lesion prior to urine collection.
  • Patient has had a biopsy to the target organ and/or lesion within 3 days before urine collection.
  • The current target pathology is a recurrence.
  • Patient has chronic indwelling urinary catheter.
  • Patient has had a urinary tract infection within the 14 days prior to sample collection.
  • If patient does not have a primary bladder , ureter or urethral cancer, patient has a history of bladder ureter, or urethral cancer.

Cases:

  • Patient has had an intervention to completely remove current target pathology.
  • The current target pathology is a recurrence.
  • Patient has multi-centric/multi-focal breast cancer with differing genetic profiles (ER/HER2/PR status differ; if multiple masses are present and not all are tested then exclude patient).
  •  Patient has bilateral breast cancer/DCIS.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 6/16/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

John Kisiel, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions